TORONTO, Aug. 30 /PRNewswire-FirstCall/ - Novadaq(R) Technologies Inc.(TSX: NDQ), a developer of real-time medical imaging systems and image guidedtherapies for the operating room, today announced that Dr. Arun Menawat,President & CEO of Novadaq, will present the corporate story, technology andhighlights, including an update on commercial development and the pipeline, atthe Thomas Weisel Partners Healthcare Conference. The conference runs fromWednesday, September 5 through Friday, September 7 at the Four Seasons Hotelin Boston. Dr. Menawat's presentation at 8:00 a.m. on Thursday, September 6will be webcast live from Novadaq's website at www.novadaq.com.
About Novadaq Technologies
Novadaq Technologies Inc. (TSX: NDQ) develops and commercializes medicalimaging systems and real-time image guided therapies for use in the operatingroom. Novadaq's proprietary imaging platform can be used to visualize bloodvessels, nerves and the lymphatic system during surgical procedures. Novadaq'sSPY(R) Imaging System, commercially available worldwide, enables cardiacsurgeons to visually assess coronary vasculature and bypass graftfunctionality during the course of open-heart surgery. Novadaq's OPTTX(R)System which received CE Mark approval in November 2006, is aimed at thediagnosis, evaluation and treatment of wet Age-related Macular Degeneration(AMD) by using the same core imaging technology that is used in the SPYImaging System. The HELIOS(TM) Imaging System, which received FDA clearance inJanuary 2007, is the first fluorescent imaging system available for use duringplastic reconstructive surgery allowing surgeons to evaluate pre- andintra-operative blood flow, as well as post-surgery perfusion. Novadaq'sLUNA(TM) Imaging System is designed to enable surgeons to visualize nervebundles during the course of urological and neurological procedures. LUNA hasbeen granted a license for use by Health Canada. Novadaq is also the exclusiveUnited States distributor of PLC Medical's CO(2) HEART LASER(TM) System forTMR (Trans-Myocardial Revascularization). Novadaq recently acquired acomprehensive portfolio of minimally invasive native tissue fluorescenceimaging technology with the vision to expand the applications for thistechnology in Novadaq's surgical markets. For more information, please visitthe company's website at www.novadaq.com.
Certain statements included in this press release may be consideredforward-looking. Such statements involve known and unknown risks,uncertainties and other factors that may cause actual results, performance orachievements to be materially different from those implied by such statements,and therefore these statements should not be read as guarantees of futureperformance or results. All forward-looking statements are based on Novadaq'scurrent beliefs as well as assumptions made by and information currentlyavailable to Novadaq and relate to, among other things, anticipated financialperformance, business prospects, strategies, regulatory developments, marketacceptance and future commitments. Readers are cautioned not to place unduereliance on these forward-looking statements, which speak only as of the dateof this press release. Due to risks and uncertainties, including the risks anduncertainties identified by Novadaq in its public securities filings; actualevents may differ materially from current expectations. Novadaq disclaims anyintention or obligation to update or revise any forward-looking statements,whether as a result of new information, future events or otherwise.
SOURCE Novadaq Technologies Inc.